Pathfinders in Biopharma cover art

Pathfinders in Biopharma

Pathfinders in Biopharma

By: RBC Capital Markets
Listen for free

About this listen

 Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.Copyright 2026 RBC Capital Markets Economics Personal Finance Politics & Government
Episodes
  • No biotech bubble – but can the sector’s rally persist through 2026?

    No biotech bubble – but can the sector’s rally persist through 2026?
    Jan 27 2026

    Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this year, according to new RBC research. Brian Abrahams, Head of Global Healthcare Research, highlights some of the classes set for new breakthroughs, and points to the potential tripwires that lie ahead as biotech looks to continue its near-historic rally.
    Show More Show Less
    13 mins
  • MindMed: Rethinking brain health with psychedelic therapy

    MindMed: Rethinking brain health with psychedelic therapy
    Sep 17 2025

    Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.
    Show More Show Less
    12 mins
  • Funding the future of retinal health with Eyepoint

    Funding the future of retinal health with Eyepoint
    Sep 3 2025

    Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

    Show More Show Less
    12 mins
No reviews yet